Tag:
Kyowa Hakko
Latest Headlines
Latest Headlines
Hematech lays off 18 after narrowing antibody focus
Hematech, a South Dakota-based biotech owned by Japan's Kyowa Hakko focused on developing antibodies in cattle, has laid off 18 workers. The layoffs--which include research positions--occurred after
Reata's CKD program wins $272M Asian pact
A fresh set of promising Phase IIa data for its lead therapy helped Irving, TX-based Reata Pharmaceuticals score a $272 million licensing pact with Kyowa Hakko Kirin covering Japan and a slate of key
Dicerna lands $124M RNAi development pact
Start-up Dicerna Pharmaceuticals, which bills itself as a second-generation RNAi developer, has found its first sizeable partner in Japan. Kyowa Hakko Kirin says it will hand over a $4 million
Sanofi inks $315M inflammation pact with Kyowa
Now that Sanofi-Aventis has finished trimming some of its marginal drug development programs, the French pharma is reloading its pipeline with a licensing deal for a preclinical antibody advanced by
Alnylam inks another Japanese development pact
Cambridge, MA-based Alnylam Pharmaceuticals has signed on to a $93 million pact with Japan's Kyowa Hakko Kogyo to develop an Respiratory Syncytial Virus therapy for Asian markets. Alnylam gets $15
Arana gains development partner for cancer program
Australia's Arana Therapeutics has struck a deal to co-develop an experimental colorectal cancer therapy with Japan's Kyowa Hakko Kogyo. Arana will receive up to $8 million in the joint venture and
